Simultaneous Islet and Kidney Transplantation in Seven Patients With Type 1 Diabetes and End-Stage Renal Disease Using a Glucocorticoid-Free Immunosuppressive Regimen With Alemtuzumab Induction
Open Access
- 1 October 2008
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 57 (10) , 2666-2671
Abstract
OBJECTIVE—The aim of this study was to evaluate the efficiency and safety of simultaneous islet and kidney transplantation in patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. RESEARCH DESIGN AND METHODS—Seven patients with type 1 diabetes and end-stage renal failure were transplanted with allogenic islets and kidneys procured from brain-dead donors. To prevent organ rejection, patients received alemtuzumab for induction immunosuppression, followed by sirolimus and tacrolimus. No glucocorticoids were given at any time. RESULTS—The median duration of follow-up was 18.3 months (range 13–31). Kidney survival was 100%. Four patients became insulin independent at 1 year. The other three reduced insulin use to less than 25% of the amount required before transplantation. Serum C-peptide levels were significantly greater posttransplant in all patients, indicating continued islet function. No major procedure-related complications were observed. CONCLUSIONS—Our results demonstrate that a steroid-free immunosuppressive regimen consisting of alemtuzumab, sirolimus, and tacrolimus is feasible for simultaneous islet and kidney transplantation. The question of whether this induction regimen is superior to more standard induction deserves large studies.Keywords
This publication has 31 references indexed in Scilit:
- The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantationTransplant International, 2006
- Steroid Sparing in Kidney TransplantationClinical Journal of the American Society of Nephrology, 2006
- Sequential Kidney/Islet Transplantation: Efficacy and Safety Assessment of a Steroid-Free Immunosuppression ProtocolAmerican Journal of Transplantation, 2006
- Alemtuzumab Induction and Prednisone-Free Maintenance Immunotherapy in Simultaneous Pancreas-Kidney Transplantation Comparison With Rabbit Antithymocyte Globulin Induction – Long-Term ResultsAmerican Journal of Transplantation, 2006
- Alemtuzumab Induction and Prednisone‐Free Maintenance Immunotherapy in Kidney Transplantation: Comparison with Basiliximab Induction—Long‐Term ResultsAmerican Journal of Transplantation, 2005
- Impact of Simultaneous Kidney–Pancreas Transplant and Timing of Transplant on Kidney Allograft SurvivalAmerican Journal of Transplantation, 2005
- Successful Simultaneous Islet-Kidney Transplantation using a Steroid-free Immunosuppression: Two-Year Follow-upAmerican Journal of Transplantation, 2004
- Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failureThe Lancet, 1999
- IMPROVED SURVIVAL IN PATIENTS WITH INSULIN-DEPENDENT DIABETES MELLITUS AND END-STAGE DIABETIC NEPHROPATHY 10 YEARS AFTER COMBINED PANCREAS AND KIDNEY TRANSPLANTATION1Transplantation, 1999
- Consensus Guidelines for the Management of Insulin‐dependent (Type 1) DiabetesDiabetic Medicine, 1993